Visita Medicitalia per info su Dr. Massimo Martino, Ematologo. Trova telefono, indirizzo dove riceve, patologie trattate e curriculum.

Attenzione: l'iscritto non si collega da più di sei mesi, i dati potrebbero essere non aggiornati.

Dr. Massimo Martino

Ematologo

Specialista in:

11 Consulti

0 Recensioni

Feed Rss Rss

Scheda vista 19.025 volte

0 News/Blog
0 Articoli
0 Speciali Salute
Indice di attività:
20% attività +20
0% attualità +0
0% socialità +0
Studio Dioscuri

Via Torrione, 2N - Via Don Minzoni, 10. 89133 Reggio Calabria - 89100 Reggio di calabria (Reggio-Calabria) (RC) - Mappa

16.346379100000035 39.3087714

Vedi dettagli

Centro Trapianti Midollo Osseo, Azienda Ospedaliera BMM, Reggio Calabria

Via Cantaffio, n1 - 89100 Reggio di calabria (Reggio-Calabria) (RC) - Mappa

15.64334830000007 38.0958254

Vedi dettagli

Centro G.I.M.A.

Via Caterina Gagliardi - 89900 Vibo valentia (Vibo-Valentia) (VV) - Mappa

16.10472709999999 38.6742602

Vedi dettagli

Ultimi consulti erogati

Componente monoclonale igg kappa
17-02-2014 - Ematologia
Visto 2.131 volte
Leucocitosi linfocitosi
08-01-2014 - Ematologia
Visto 4.380 volte
Visto 3.966 volte
Neutrofilia
25-11-2011 - Ematologia
Visto 2.548 volte
Globuli rossi
18-11-2011 - Ematologia
Visto 924 volte

Visualizza tutti i consulti

Informazioni professionali

Laureato in Medicina e Chirurgia nel 1990 presso Università di Messina. Iscritto all'Ordine dei Medici di Reggio-Calabria.

Verifica dati su FNOMCeO.it »

Note e interessi

Medico Ematologo,
Mieloma Muliplo,
Trapianto di Midollo Osseo
Linfoma
Leucemia acuta
Donazione e Raccolta Cellule Staminali

Curriculum vitae






 
 






Pubblicazioni su riviste scientifiche
1.    Plerixafor added to Chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.Attolico I, Pavone V, Ostuni A, Rossini B, Musso M, Crescimanno A, Martino M, Iacopino P, Milone G, Tedeschi P, Coluzzi S, Nuccorini R, Pascale S, Di Nardo...

Leggi tutto

E, Olivieri A. Biol Blood Marrow Transplant. 2011 Jul 23. [Epub ahead of print] (impact factor 3.275)
2.    Imatinib mesylate in T-cell large granular lymphocyte leukemia associated with chronic graft-versus-host disease. Fedele R, Martino M, Dattola A, Cuzzola M, Irrera G, Messina G, Console G, Iacopino P. Leuk Lymphoma. 2011 Jun 12 (impact factor 2.492)
3.    Pulmonary micro-embolism in a healthy donor following G-CSF administration for mobilization of hemopoietic progenitor cells. Martino M, Massara E, Irrera G, Messina G, Barreca G, Console G. Bone Marrow Transplant. 2011 Apr 4. [Epub ahead of print]  (impact factor 2.998)
4.    Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience. Martino M, Console G, Dattola A, Callea I, Messina G, Moscato T, Massara E, Irrera G, Fedele R, Gervasi A, Bresolin G, Iacopino P. Bone Marrow Transplant. 2009 Aug;44(3):163-8. (impact factor 2.998)
5.    Wernicke's encephalopathy after allogeneic stem cell transplantation. Messina G, Quartarone E, Console G, Irrera G, Martino M, Pucci G, Le Piane E, Branca D, Cafarelli F, Gangemi A, Iacopino P. Tumori. 2007 Mar-Apr;93(2):207-9. (impact factor 0.86)
6.    Utility of the clinical practice of administering thrombophilic screening and antithrombotic prophylaxis with low-molecular-weight heparin to healthy donors treated with G-CSF for mobilization of peripheral blood stem cells. Martino M, Luise F, Oriana V, Console G, Moscato T, Mammì C, Messina G, Massara E, Irrera G, Piromalli A, Lombardo VT, Laganà C, Iacopino P. Tumori. 2007 Mar-Apr;93(2):155-9. (impact factor 0.86)
7.    Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients. Martino M, Console G, Callea V, Stelitano C, Massara E, Irrera G, Messina G, Morabito F, Iacopino P. Eur J Haematol. 2007 Jan;78(1):35-40. (impact factor 2.345)
8.    Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Martino M, Praticò G, Messina G, Irrera G, Massara E, Messina G, Console G, Iacopino P. Eur J Haematol. 2006 Nov;77(5):410-5 (impact factor 2.345)
9.    Predictive factors that affect the mobilization of CD34(+) cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF). Martino M, Callea I, Condemi A, Dattola A, Irrera G, Marcuccio D, Messina G, Pontari A, Pucci G, Console G, Lacopino P. J Clin Apher. 2006 Oct;21(3):169-75. (impact factor 1.471)
10. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients. Martino M, Console G, Irrera G, Praticò G, Stelitano C, Callea V, Morabito F, Quartarone E, Musolino C, Piro E, Brugiatelli M, Iacopino P. Am J Hematol. 2006 Dec;81(12):973-8 (impact factor 2.61)
11. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Bengala C, Zamagni C, Pedrazzoli P, Matteucci P, Ballestrero A, Da Prada G, Martino M, Rosti G, Danova M, Bregni M, Jovic G, Guarneri V, Maur M, Conte PF; Gruppo Italiano Trapianto Midollo Osseo (GITMO) Group. Br J Cancer. 2006 Apr 10;94(7):1016-20. (impact factor 4.346)
12. 'In vivo' time course of plasma myeloperoxidase levels after granulocyte colony-stimulating factor-induced stem cell mobilization. Morabito F, Tomaino A, Cristani M, Martino M, Minciullo PL, Saija A, Gangemi S. Transfus Med. 2005 Oct;15(5):425-8. (impact factor 1.808)
13. Modification of the content of plasma protein carbonyl groups in donors after granulocyte colony stimulating factor-induced stem cell mobilization. Morabito F, Tomaino A, Cristani M, Cimino F, Martino M, Minciullo PL, Calabrò C, Saija A, Gangemi S. Transfus Apher Sci. 2005 Oct;33(2):141-6 (impact factor 0.970)
14. Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting. Galimberti S, Benedetti E, Morabito F, Fazzi R, Pacini S, Andreazzoli F, Martino M, Iacopino P, Petrini M. Transpl Immunol. 2005 Dec;15(2):173-7(impact factor 2.296)
15. Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation. Galimberti S, Benedetti E, Morabito F, Petrini I, Battolla B, Papineschi F, Fazzi R, Ciabatti E, Martino M, Cuzzola M, Console G, Iacopino P, Petrini M. Leuk Res. 2006 May;30(5):529-35. (impact factor 2.358)
16.  Harvesting peripheral blood progenitor cells from healthy donors with a short course of recombinant human granulocyte-colony-stimulating factor. Martino M, Morabito F, Callea I, Pontari A, Irrera G, Pucci G, Dattola A, Messina G, Console G, Iacopino P. Transfus Med. 2005 Aug;15(4):323-8 (impact factor 1.808)
17. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Galimberti S, Benedetti E, Morabito F, Papineschi F, Callea V, Fazzi R, Stelitano C, Andreazzoli F, Guerrini F, Ciabatti E, Martino M, Nobile F, Iacopino P, Petrini M. Leuk Res. 2005 Aug;29(8):961-6. (impact factor 2.358)
18. Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim. Martino M, Console G, Irrera G, Callea I, Condemi A, Dattola A, Messina G, Pontari A, Pucci G, Furlò G, Bresolin G, Iacopino P, Morabito F. J Clin Apher. 2005 Oct;20(3):129-36. (impact factor 1.471)
19. Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients. Martino M, Oliva E, Console G, Stelitano C, Fujo M, Messina G, Irrera G, Pucci G, Mandaglio R, Callea V, Nobile F, Iacopino P, Morabito F. Support Care Cancer. 2005 Mar;13(3):182-7(impact factor 2.089)
20. High-dose chemotherapy with mitoxantrone + melphalan and autologous stem cell rescue in metastatic breast cancer patients: a study of feasibility and tolerability. Martino M, Morabito F, Console G, Irrera G, Pucci G, Penna G, Dattola A, Callea I, Pontari A, Condemi A, Messina G, Nardi M, Cicero G, Molica S, Palazzo S, Iacopino P. Tumori. 2003 Sep-Oct;89(5):492-6 (impact factor 0.86)
21. Differences in transplant-related complications between hematologic malignancies and solid tumors receiving high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Martino M, Morabito F, Console G, Irrera G, Messina G, Pucci G, Nardi M, Nobile F, Molica S, Cicero G, Palazzo S, Peta A, Musolino C, Iacopino P. Tumori. 2003 Jul-Aug;89(4):385-90 (impact factor 0.86)
22. Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. Galimberti S, Morabito F, Guerrini F, Palumbo GA, Azzará A, Martino M, Benedetti E, Di Raimondo F, Petrini M. Br J Haematol. 2003 Feb;120(3):405-12. (impact factor 4.597)
23. Basiliximab for the treatment of graft rejection in haploidentical peripheral blood stem cell transplantation. Messina G, Quartarone E, Fujo M, Irrera G, Console G, Martino M, Mandaglio R, Morabito F, Iacopino P. Haematologica. 2002 Dec;87(12):ECR4 (impact factor 6.416)
24. Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. Morabito F, Martino M, Stelitano C, Oliva E, Kropp M, Irrera G, Console G, Fujo M, Messina G, Molica S, Callea V, Iacopino P. Haematologica. 2002 Nov;87(11):1192-9 (impact factor 6.416)
25. Systemic aspergillosis in a patient with non-Hodgkin's lymphoma developing acute graft-versus-host disease after autologous peripheral blood stem cell transplantation. Messina G, Quartarone E, Console G, Cuzzola M, Iacopino O, Martino M, Irrera G, Morabito F, Iacopino P. Haematologica. 2002 Jul;87(7):ECR22 (impact factor 6.416)
26. Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy. Morabito F, Irrera G, Oliva E, Console G, Martino M, Pucci G, Messina G, Barbaro P, Palazzo S, Iacopino P. Bone Marrow Transplant. 2001 Nov;28(9):883-8 (impact factor 2.998)
 
27. Graft-versus-lymphoma effect in a patient with a refractory low-grade lymphoma. Martino M, Irrera G, Messina G, Pucci G, Morabito F, Iacopino P. Haematologica. 1999 Dec;84(12):1156-7 (impact factor 6.416)
28. High-dose etoposide enables the collection of peripheral blood stem cells in patients who failed cyclophosphamide-induced mobilization. Pucci G, Irrera G, Martino M, Messina G, Console G, Morabito F, Iacopino P. Br J Haematol. 1998 Mar;100(3):612-3 (impact factor 4.597)
29. Two consecutive courses of rh-G-CSF-mobilized peripheral blood stem cells for primary marrow alloengraftment failure: case report. Martino M, Pucci G, Irrera G, Messina G, Morabito F, Iacopino P. Haematologica. 1996 Sep-Oct;81(5):464-7 (impact factor 6.416)
30. Fractionated infusions of cryopreserved stem cells may prevent DMSO-induced major cardiac complications in graft recipients. Martino M, Morabito F, Messina G, Irrera G, Pucci G, Iacopino P. Haematologica. 1996 Jan-Feb;81(1):59-61 (impact factor 6.416)
31. Thrombotic thrombocytopenic purpura: a rare late complication of allogeneic bone marrow transplantation. Pucci G, Martino M, Morabito F, Iacopino P, Arcese W, Iori AP, Lombardo VT, L'Abbate A, Santostefano M, Nobile F. Haematologica. 1994 Jul-Aug;79(4):371-3 (impact factor 6.416)
32. Magnetic resonance imaging of the bone marrow in aplastic anemia. Description of a case Tamburrini O, Della Sala M, Sessa M, Pucci G, Martino M. Radiol Med. 1993 Nov;86(5):707-9. (impact factor 6.341)
 

Sito web

Attività su Medicitalia

Il Dr. Massimo Martino è specialista di medicitalia.it dal 2011.